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Background/aim: Continuous renal replacement therapy (CRRT) has significant benefits in the treatment of critically ill children.
The objective of this study is to describe the treatment indications, methods, demographics, and outcome of the patients who received
CRRT in our pediatric intensive care unit and neonatal care unit, and, according to these results, we also aim
to make improvements in our unit-based interventions.
Materials and methods: In this single-centered study, we retrospectively evaluated medical charts of the patients admitted to our
intensive care units and received CRRT between February 2010 and November 2015.
Results: Fifty of 60 patients were included in this study. Newborns made up 28% (n = 14) of the patients. The mean body weight
was 18.4 kg (2.3-98 kg). CRRT indications were fluid overload (30%), acute kidney injury (40%), metabolic disease (24%), electrolyte
impairment (4%), and drug intoxication (2%). The most common method of CRRT was continuous venovenous hemodiafiltration
(CVVHDF) (72%). The mean duration of CRRT was 135 hours (1-864) and totally 143 filters, polyarylethersulfon (n = 23.46%) and
polyacrylonitrile (n = 27.54%) were used. Overall survival was 42%. The survival rate of newborns was significantly higher (P = 0.046).
Conclusion: CRRT is a lifesaving method that can be applied to critically ill children with acute kidney injury and fluid overload at any
age and weight by experienced teams.
Key words: Continuous renal replacement therapy, acute kidney injury, critically ill children, fluid overload, hemodiafiltration,
hemofiltration

1. Introduction
Acute kidney injury (AKI) is a common diagnosis in
pediatric and neonatal intensive care units (PICU and
NICU). It can be secondary to many conditions such
as cardiac arrest, sepsis, shock states, heart failure, drug
toxicity, acute hypoxic respiratory failure, cardiac surgery,
multiorgan failure, liver disease. AKI is solely a factor for
morbidity and mortality in critically ill children. Fluid
overload (FO) is the biggest trouble in critically ill children
when renal dysfunction develops. As FO is harmful to all
organs especially cardiovascular and respiratory system,
cardiovascular disorders, pulmonary edema, hypotension,
and severe hypoxemia are seen when FO is over 10% [1-5].
Therefore, we must intervene AKI and FO. Some studies
demonstrated that more than 10% of FO is an independent
risk for prolonged mechanical ventilation and length of
stay (LOS) in PICU, also for mortality [1]. Mortality rates

are relatively high in pediatric renal failure, ranging from
66% to 90% in PICU [3].
Renal replacement therapies (RRT) in pediatric
patients have developed rapidly since the 1980s, as an
alternative to intermittent hemodialysis (IHD) which has
disadvantages like cardiovascular instability, respiratory
problems, catheter-related difficulties, and peritoneal
dialysis (PD) having slow and low ultrafiltration efficiency.
CRRT provided significant advantages in the treatment of
critically ill patients [6]. The two most important factors
affecting the choice of dialysis treatment are the indication
of dialysis treatment and the clinical condition of the
patient. The size of the molecules to be removed and the
working principle of dialysis should be considered. The
most important advantage of CRRT is a gradual solute and
fluid excretion, mimicking renal functions and physiology,
and helping to create conditions that will help the kidneys
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heal without compromising the hemodynamic balance
[7,8]. In this study, we report our CRRT experiences about
critically ill children in NICU and PICUs.
2. Materials and methods
2.1. Collection and evaluation of data
We retrospectively evaluated the patients treated with
CRRT and hospitalized in NICU and PICU of Ankara
University Children’s hospital between February 2010 and
November 2015. The ratio of total fluid intake to a fluid
loss greater than 10% is defined as fluid overload. Also, the
patient was oliguric/anuric and has pediatric risk, injury,
failure, loss, end-stage renal disease (pRIFLE) score stage
3 or 4 [9] is defined as AKI. Another indication was the
metabolic disease that is unresponsive to standard medical
treatments and occurs in the presence of dialyzable toxic
metabolic collection such as leucine, ammonium, refractory
metabolic acidosis. The last group was severe poisoning
with dialyzable toxic matter ingestion.
Once there was an indication of CRRT, an appropriate
size vascular access was provided, and then CRRT mode
was determined. Priming was performed after establishing
the suitable circuit for the patient’s BW (body weight)
and anticoagulation was started to all patients. Patients’
demographic characteristics (age, sex), BW, primary disease,
duration of hospitalization, The Pediatric Risk of Mortality
(PRISM), and Pediatric Logistic Organ Dysfunction
(PELOD) scores were recorded during admission.
Indications of CRRT, baseline biochemistry, (BUN,
creatinine, sodium, potassium), and hourly urine output,
based on the 24-h urine output were recorded before
the onset of CRRT. The choice of CRRT modes, which
are continuous venovenous hemodialysis CVVHD),
continuous venovenous hemodiafiltration (CVVHDF),
continuous venovenous hemofiltration (CVVH)], vascular
access regions, CRRT initial settings, complications,
other supportive modalities [Extracorporeal membrane
oxygenation (ECMO), mechanical ventilation, plasma
exchange], and the overall CRRT outcome were evaluated.
Circuit and filter renewals, problems related to the machine,
patient-related problems, factors related to clotting in the
circuit were analyzed. We used to Gambro-Baxter (USA)
dialysis machine and its proper filters. All patients were
followed up with activated partial thromboplastin (APTT)
time at appropriate intervals, and activated clotting time
(ACT), which is a method that is easier and quicker, is
applied additively to the patients who had a hemodynamic
disorder and bleeding tendency.
The decision to terminate the CRRT is based on the
recovery from the current problem like FO, AKI with
good diuresis, insuperable issue, and deceased patients.
Treatment success was defined as the ability to perform the
planned CRRT program as long as the patient needed.

2.2. Statistical evaluation of data
SPSS 15.0 (SPSSInc., Chicago, IL, USA) package program
was used in the evaluation of the data. Chi-square and/or
Fisher’s exact test was used to compare categorical variables.
Student’s T-test and/or one-way analysis of variance
(ANOVA) was used for the continuous measurement
values according to the number of categories. Analysis
results were summarized by mean±standard deviation,
median values, frequency distributions, and percentages,
and P < 0.05 was considered statistically significant.
3. Results
Sixty children receiving CRRT in PICU and NICU between
February 2010 and November 2015 were included in the
study; however, 10 of them were excluded because of the
missing data.
A total of 40% of all patients were female. Ages ranged
from 3 days to 19 years; Nnwborns were constructed 28%
(n = 14) of the group. The mean BW was 18.4 ± 20.1 kg
(2.3-98 kg). The patients were further grouped as <5 kg,
5-10 kg, 10-20 kg, 20-50 kg and > 50 kg. The group with
the highest number of patients was infants weighing less
than 5 kg (n = 15, 30%).
Three of the 50 patients were still in hospital at the
end of the study; therefore, the mean LOS in PICU/NICU
for the remaining 47 patients was 13.1 ± 12.1 (1-47) days.
PRISM and PELOD scores were 19 (6-45) and 20 (10-33),
respectively. All the patients were received mechanical
ventilator support, 8 (16%), and 12 (24%) of them were
treated with ECMO and plasma exchange, respectively.
The median PRISM score of the patients treated with
ECMO was 28 (15-45) and the PELOD score was 32 (2243). Laboratory findings before CRRT was; BUN 34 ± 33.9
(1-161) mg/dL, creatinine 1.35 ± 1.01 (0.08-4.6) mg/dL,
sodium 138 ± 7.6 (124-158) mEq/L and potassium was
4.3 ± 1.8 (2-9.8) mEq/L. The 24-h urine output of the day
before the onset of CRRT was 2.1 ± 2.8 (0-12.2) mL/kg/h.
Indication categories for CRRT are given in Table 1.
The most common modality was CVVHDF (72%) and the
least modality was CVVH (4%).
Double-lumen hemodialysis catheters were placed
into internal jugular vein (50%), femoral vein (36%),
and subclavian vein (12%), and CRRT was applied from
ECMO connection site in one patient. The median size of
the catheter was 7 (5-11) F.
The mean duration of CRRT was 135 h (1-864), a sum
of 143 filters [23 (HF20, 46%), polyarylethersulfon, 14
polyacrylonitriles (AN 69) (M60 28%), 13 M100 (26%)]
were used. Some patients completed the treatment period
with one circuit, while, in others, circuit replacement
was required due to clot formation. The mean circuit
lifespan was 39.1±27.5 (0.5-120) h. When we compared
the patients having mean circuit lifespan >39.1 and <39.1
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Table 1. Indications of CRRT.
Indication

Patient (n)

%

Fluid overload

15

30

Acute kidney injury

20

40

Metabolic disease
Urea Cycle defect (n = 6)
Methylmalonic aciduria (n = 2)
Maple syrup urine disease (n = 2)
Lactic acidosis (n = 2)

12

24

Electrolyte impairment
Hyperpotassemia (n = 2)

2

4

Drug intoxication
Theophylline (n = 1)

1

2

h, there was no difference in catheter sizes (P = 0.341) and
circuit type (P = 0.369). However, 62.5% (n = 10) of 16
patients used a 9F catheter, the circuit lifespan was longer
than the average. There was no significant relationship
between catheter entry site and circuit lifespan (P = 0.537).
Priming was performed with saline (32%), 5%
albumin (24%), and blood (44%) and heparin was used
for anticoagulation in all patients and it was changed to
citrate in bleeding patients. CRRT initial settings were
recorded according to CRRT models and BW (Table
2). The most common side effect related to CRRT was
hypotension (56%) (Table 3).
3.1. Factors affecting outcomes and survival
Fifty patients receiving CRRT had 6753 h of operation time
with an 86% success rate for all patients. The most common
problem in CRRT was the circuit changes due to occlusion
in the circuits. CRRT terminated earlier than expected in
7 patients because of technical reasons (2 patients) and
hemodynamic instability (5 patients). The overall survival
rate was 42% and all survival-related factors are shown in

Table 4. Survival rates in newborns were (64.2%), which
was significantly higher when compared with others (P =
0.046) (Figure).
The survival rates according to BW (<5 kg, 5-10 kg,
10-20 kg, 20-50 kg,> 50 kg) was evaluated and the highest
survival rate 66.7% was achieved in infants less than 5 kg.
However, there was no statistically significant difference
between the weight groups (P = 0.190). The smallest
survived patient was 3 kg. The highest treatment success
was achieved in children with BW > 50 kg, but the success
rates were not different between groups (P = 0.873).
The highest survival rate was achieved in patients
with primary renal disease (n = 3, 100%), and there was
no survivor in the group of genetic disorders. All patients
were also classified as those with a primary disease (n =
45) and those without (n = 5), and the survival rates were
40% and 60%, respectively. The presence of the primary
disease has a negative effect on survival (P = 0.04). PRISM
and PELOD scores were significantly different between
the survivors and others (P = 0.016 vs. P = 0.001). There
was no significant difference between survival rates and
the length of hospitalization in PICU/NICU (P = 0.192).
Sodium, BUN, and creatinine levels were similar, but
potassium levels and urine output were different between
survivors and others. There was an inverse correlation
between potassium level and survival (P = 0.032) and also
the survival rate was better in patients with higher urine
output (P = 0.026).
All patients received mechanical ventilator support.
ECMO was administered to 8 patients and all have died.
As a result, there was a statistically significant difference
in survival between ECMO and the nonECMO group (P
= 0.015). Plasma exchange was not found to be associated
with survival (P = 0.979).
A patient with the diagnosis of theophylline
intoxication was also survived. The highest survival
rate was achieved in patients having just fluid overload
(60%). There was no survivor among the patients treated

Table 2. CRRT initial settings by body weights.
Body weight
(kg)

Blood flow rate
(mL/kg/min)

Dialysate flow rate
(mL/1,73 m²/h)

Replacement fluid
flow rate (mL/kg/h)

Ultrafiltration rate
(mL/kg)

<5 kg (n =15)

8.3 (2.6-10.9)

60 (30-200)

120 (0-2000)

2 (0-10)

5-10 kg (n = 14)

6.2 (2.5-9.3)

150 (30-200)

200(0-560)

2.6 (0-7)

10-20 kg (n = 5)

4.8 (4-5.7)

200 (150-800)

400(0-950)

1(0-3.5)

20-50 kg (n = 13)

3.7 (2-4.5)

540 (0-1400)

1100 (0-1700)

2.1 (0-6)

>50 kg (n = 3)

2 (2-3)

1800 (1000-2400)

2000 (2000-3500)

3 (1-3)

Total (n = 50)

5.2 (2-10.9)

150 (0-2400)

265 (0-3500)

2.4 (0-10)

*The results are given as average, minimum, and maximum values.
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Table 3. Frequency of CRRT side effects.
Side effect

Patient (n)

%

Hypotension

28

56

Thrombocytopenia

24

48

Hypophosphatemia

22

44

Hypothermia

19

38

Hypokalemia

16

32

Bleeding

11

22

Hypocalcemia

10

20

Hypovolemia

3

6

Infection

2

4

with CRRT with the indication of electrolyte imbalance
(hyperpotassemia, n = 2), the second-worst survival rate
was among the acute kidney injury group (19%). There
was no homogeneous distribution of mortality among the
indications categories (P = 0.022)
4. Discussion
Continuous renal replacement therapies are life-saving
treatments for critically ill children and fluid burden,
and removal of toxic substances and metabolites were
restored. CRRT data are most widely obtained from the
“prospective pediatric continuous renal replacement
therapy” (ppCRRT) records [10]. The survival rate in our
study is 42%, which is comparable with other single-center
publications [11,12].
CRRT in young children with low-weights requires
additional evaluation due to differences in extracorporeal
circulating blood volume, high blood flow rates, and the
presence of different underlying diseases and indications
for this age group. Askenazi et al. [13] reported the results
of children with a BW of ≤10 kg in the ppCRRT database,
the overall survival rate was 43%, survival rates of the <
5 kg and 5-10 kg are 44% and 42%, respectively. They
reported higher survival rates in children > 10 kg (64%) in
the same database. Symons et al. [14] reviewed the records
of 85 patients from 5 centers in the USA, with BW ≤10 kg,
retrospectively. Overall survival was 38% and the survival
rates of the < 3 kg and >3 kg are 25% (4 of 16 patients) and
41%, respectively. The smallest infant who was survived
was 2.3 kg. In our study, conversely, the survival rate of
newborns and BW <5 kg group seemed to be higher than
the others (64.3% and 66.7%, respectively), but this is not
statistically significant (P = 0.190). The lowest BW among
the survivors is 3 kg. This condition may be due to the fact
that the patients in the study group don’t distribute equally
in all age groups and the most common CRRT indication
in newborns is metabolic disease which is known to have

better survival rates with CRRT treatment [15]. There
were technical difficulties of CRRT for the patients with
lower BW’s; however, a better survival rate was achieved
in our center probably due to high quality technical and
personnel support.
It is known that survival is associated with the primary
disease in CRRT. According to the ppCRRT registry,
survival rates were found to be 100% for drug intoxication,
84% for renal disease, 83% for tumor lysis syndrome,
and 73% for congenital metabolic diseases [16]. In our
study, the most common primary disease is metabolic
disorders (24%). The group with the highest survival rate
was renal disease group (100% survival in 3 patients). The
percentage of the patients with a primary disease was 40%
and this affects adversely the survival rate. Besides, 10%
of the study group was organ transplanted patients (bone
marrow, n = 4; liver, n = 1) and the survival rate among
them was 40%, which is comparable to 45% survival rate
in the study evaluating 51 patients requiring CRRT with
stem cell transplantation [17].
In the ppCRRT registry, the most common indication
for treatment is fluid overload with electrolyte imbalance.
The highest achieved survival rate was 68% for electrolyte
imbalance alone and the worst survival rate is in the group
having electrolyte imbalance with fluid overload (51%)
[10]. In another publication, patients with AKI due to
different reasons treated with CRRT, the most common
CRRT indication was fluid overload [18], also in our
study, the most common indication for CRRT was AKI
(40%) and the best survival rate is in the group of fluid
overload (60%). However, due to the retrospective design
of the study, the amount of fluid overload could not be
determined. There was no survivor in the electrolyte
imbalance group and the worst survival rate among other
causes was found to be in the AKI group (20%).
Studies have shown that the PRISM II score is lower
in the survivors [10,16]; however, this score is not a good
predictor for children with AKI [19]. Goldstein et al. [20]
reported that PRISM II scores recorded at admission to
PICU were not different between the survivors and others,
but it was higher at the beginning of CRRT and this may
be associated with increased fluid burden. In our study
group, the PRISM and PELOD scores recorded during the
initial admission of patients were significantly lower in the
survivors.
Also, high 24-h urine output (the day before the
onset of CRRT) and low potassium levels found to have
a positive effect on survival. This result may be related to
better kidney functions and lower FO.
In the ppCRRT registries, CVVHD was applied to 48%
of patients, CVVHDF 30%, CVVH 21%, and SCUF 1%
[10], and the most common modality were CVVHD (60%)
in the group of patients <10 kg, too [13]. In another study
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Table 4. Survival related factors.
Survivors

Exitus

P-value

Female

(n = 8) 16%

(n = 12) 24%

Male

(n = 1) 26%

(n = 17) 34 %

Body weight (kg)

7.5

16.5

0.084

Age (month)

4

37

0.017

PRISM score

20

29

0.016

PELOD score

17

31

0.001

Duration of hospitalization in PICU/NICU (days)

16.5

5

0.192

BUN (mg/dL)

13

27

0.157

Creatinine (mg/dL)

1.03

1.26

0.120

Sodium (mEq/L)

137

138

0.679

Potassium (mEq/L)

3.7

4.3

0.032

Urine Output (ml/kg/h)

1.82

0.78

0.026

CRRT duration (hours)

72

72

0.992

CVVHF

(n=0)

(n= 2) 4%

CVVHD

(n= 7) 14%

(n= 5) 10%

CVVHDF

(n= 14) 28%

(n= 22) 44%

Femoral

(n= 5) 10%

(n= 13) 26%

Jugular

(n= 13) 26%

(n= 11) 22%

Subclavian

(n= 3) 6%

(n= 4) 8%

ECMO set

(n= 0)

(n= 1) 2%

Catheter size

7

9

0.435

Blood flow rate

6.4

4.4

0.02

Mean circuit lifespan (hours)

42

30

0.283

Demographic data
0.815

Intensive Care Monitoring

Biochemical data at the onset of CRRT

CRRT modality
0.321

Vascular access location

0.277

CRRT prescription

in pediatric patients, survival was higher when using the
convective dialysis method (CVVH), but when metabolic
disorders excluded, the significance disappeared [14]. In
our study, CVVHD (72%) was the most frequent modality
and there was no significant difference in survival between
the diffusive and convective methods.
The effect of catheter entry site or size on CRRT
performance in childhood remains unclear. In a study,
catheter diameter has been reported to have a positive
effect on the circuit lifespan [10]. There was no difference
in catheter size or location between survivors and others
in the ppCRRT registry [21]. Hackbarth et al. [22] showed
that using larger diameter catheters, internal jugular veins
for the access, and CVVHD application as factors will
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extend the circuit lifespan. To optimize circuit lifespan,
the use of internal jugular vein in patients who need a <10
F catheter is advised. There was no difference in catheter
size or catheter location between survivors and others in
our study. The effect of catheter size and catheter location
on circuit lifespan was not determined.
Factors affecting the filter lifespan in patients with
CRRT have not yet been fully determined. In a prospective
study, the mean circuit lifespan was reported as 31 (1-293)
h. There was no relationship between age, BW, diagnosis,
vascular access site, blood flow rate, ultrafiltration rate,
inotropic drug intake, and filter life. The use of heparin
(20 U/kg/h), CVVHD application, filters with surface area
0.4-0.9 m², ≥6.5 F catheter size may prolong the filter life
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Figure. Survival rates of newborns and others.

[23]. In another study, the effect of BW on circuit lifespan
was questioned, and no difference was found in terms of
circuit life between BW <5 kg and 5-10 kg [13]. The mean
filter life was 39.1 h in our study, the longest circuit lifespan
determined by using an M60 with a 7F catheter was 120 h
in a patient whose BW is 20 kg. The shortest circuit lifespan
life is 0.5 h in a 9-day newborn with metabolic disease.
An HF20 circuit with an 8F catheter was used, and CRRT
was terminated because of hemodynamic instability of the
patient.
Although CRRT has many complications in critically
ill children, adequate studies have not been conducted.
In a prospective single-center study, hypotension was
seen in 30.4% and hemorrhage in 10.3% at the onset of
CRRT, and these were not related to other factors [24].
In our study, the most frequent side effect of CRRT was

hypotension (56%) and rarest side effect was infection
(4%). Hypotension may be related to hemodynamic
instability of patients, which gets worse after CRRT.
This article has limitations because of the retrospective
design of the study. Descriptive information such as fluid
overload amount and factors affecting circuit lifespan
could not be obtained.
In conclusion, CRRT is a lifesaving method in critically
ill children with AKI and FO. In NICU and PICUs, CRRT
can be performed in newborns and children at any age and
weight by experienced teams. The success of this treatment
depends on the patient’s clinical situation, underlying
curable disease, controlling technical problems, and
the experience of the teams. Eventually, CRRT is a very
important extracorporeal treatment method and a
lifesaving option in intensive care units.
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